Loading data for ROIV — first visit, this takes a few seconds.
Roivant Sciences Ltd. (ROIV)
NasdaqGS: ROIV
· 实时价格 · USD
41.38
-0.10 (-0.24%)
收盘价： Sep 09, 2026, 3:59 PM
41.96
+0.35%
盘后: 7:54 PM
股价、关键数字和最新消息，都在这一页。
Roivant Sciences Ltd.（ROIV）股价、分析与数据
-0.25% (1D)
| 买价 | 41.39 |
| 市值 | 30.2B |
| 营收（TTM） | 7.53M |
| 净利润（TTM） | -266M |
| 1.12 | |
| -0.47 | |
| n/a | |
| -24.34 | |
| 市净率（TTM） | 7.14 |
| 市销率（TTM） | 4009.60 |
| 财报日期 | Nov 9, 2026 |
| 卖价 | 41.26 |
| 成交量 | 376,886 |
| 20日均量 | 6,597,504 |
| 开盘价 | 41.39 |
| 前收盘价 | 41.48 |
| 日内区间 | 41.13 - 41.81 |
| 52周区间 | 13.39 - 42.50 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; n...
公司完整简介财报意外
Roivant Sciences 已于 Aug 6, 2026 发布季度财报：
- 营收为 $1.44M 低于预期 $0, ， -33.55% 同比下滑.
- 每股收益为 -0.34 超出预期 0.02, ， -36.00% 同比下滑.
第 1 页，共 2 页